lutetium has been researched along with Brain Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadzadehfar, H; Essler, M; Schlenkhoff, C; Schwarz, B; Wei, X | 1 |
| Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J | 1 |
| Hens, M; Vaidyanathan, G; Welsh, P; Zalutsky, MR | 1 |
| Bigner, DD; Hens, M; Vaidyanathan, G; Zalutsky, MR; Zhao, XG | 1 |
| Dorn, HC; Fatouros, PP; Fuller, CE; Shultz, MD; Wilson, JD; Zhang, J | 1 |
| Bulte, JW | 1 |
| Bettinardi, V; Gianolli, L; Gilardi, MC; Picchio, M; Presotto, L; Rapisarda, E | 1 |
| Katoh, N; Kuge, Y; Okamoto, S; Onimaru, R; Shiga, T; Shirato, H; Suzuki, R; Takeuchi, W; Tamaki, N; Tsuchiya, K; Yasuda, K | 1 |
| Bigner, DD; Hens, M; Pegram, C; Yordanov, AT; Zalutsky, MR | 1 |
| Blatner, G; Cheson, BD; Ivy, SP | 1 |
10 other study(ies) available for lutetium and Brain Neoplasms
| Article | Year |
|---|---|
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Topics: Aged; Brain Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2017 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Gastrins; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Purines; Radioisotopes; Signal Transduction; Temozolomide | 2016 |
Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; ErbB Receptors; Glioma; Isotope Labeling; Ligands; Lutetium; Macrocyclic Compounds; Mice; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2009 |
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; ErbB Receptors; Flow Cytometry; Glioma; Heterocyclic Compounds, 1-Ring; Humans; Isothiocyanates; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Stereoisomerism; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
Topics: Animals; Brachytherapy; Brain Neoplasms; Coordination Complexes; Disease Models, Animal; Female; Fullerenes; Glioblastoma; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Mice, Nude; Nanotechnology; Neoplasm Transplantation; Radioisotopes; Radionuclide Imaging | 2011 |
Science to practice: can theranostic fullerenes be used to treat brain tumors?
Topics: Animals; Brachytherapy; Brain Neoplasms; Fullerenes; Glioblastoma; Lutetium; Mice; Mice, Nude; Radioisotopes | 2011 |
Physical performance of the new hybrid PET∕CT Discovery-690.
Topics: Algorithms; Brain Neoplasms; Equipment Design; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lutetium; Models, Statistical; Phantoms, Imaging; Positron-Emission Tomography; Reproducibility of Results; Silicates; Tomography Scanners, X-Ray Computed; Tomography, X-Ray Computed; Whole Body Imaging; Yttrium | 2011 |
[18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Case-Control Studies; Cell Hypoxia; Female; Humans; Laryngeal Neoplasms; Lutetium; Male; Middle Aged; Misonidazole; Mouth Neoplasms; Multimodal Imaging; Nasopharyngeal Neoplasms; Nasopharynx; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Semiconductors; Silicates; Thyroid Neoplasms; Tomography, X-Ray Computed | 2013 |
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain; Brain Neoplasms; Cell Line, Tumor; Glioma; Hydrocarbons, Acyclic; Lutetium; Macrocyclic Compounds; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Organ Specificity; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tenascin; Tissue Distribution | 2007 |
Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Gadolinium; Humans; Lutetium; Metalloporphyrins; Photosensitizing Agents | 1999 |